Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients

Z. Y. G. J. van Lierop; A. A. Toorop; E. M. E. Coerver; E. A. J. Willemse; E. M. M. Strijbis; N. F. Kalkers; B. Moraal; F. Barkhof; C. E. Teunissen; J. Killestein; Z. L. E. van Kempen

doi:https://doi.org/10.1177/20552173211013831

Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients

Z. Y. G. J. van Lierop, A. A. Toorop, E. M. E. Coerver, E. A. J. Willemse, E. M. M. Strijbis, N. F. Kalkers, B. Moraal, F. Barkhof, C. E. Teunissen, J. Killestein, Z. L. E. van Kempen

Research output: Contribution to journal › Article › Academic › peer-review

12 Citations (Scopus)

Abstract

Ocrelizumab is often used as an alternative therapy in natalizumab-treated MS patients at risk for progressive multifocal leukoencephalopathy (PML). Our objective was to assess efficacy and safety of JC-virus positive patients switching (either directly or indirectly) from natalizumab to ocrelizumab. Forty-two patients were included from an observational cohort (median follow-up 21 months). No evidence of disease activity was found in 83% of direct switchers and 50% of indirect switchers. Two direct switchers were diagnosed with carry-over PML. Our data support a direct switch for adequate disease suppression, although carry-over PML illustrates the dilemma when choosing between a direct or indirect switch.

Original language	English
Journal	Multiple sclerosis journal - experimental, translational and clinical
Volume	7
Issue number	2
DOIs	https://doi.org/10.1177/20552173211013831
Publication status	Published - 2021

Keywords

JC virus
Multiple sclerosis
disease activity
natalizumab
ocrelizumab
progressive multifocal leukoencephalopathy

Access to Document

https://doi.org/10.1177/20552173211013831

Cite this

van Lierop, Z. Y. G. J., Toorop, A. A., Coerver, E. M. E., Willemse, E. A. J., Strijbis, E. M. M., Kalkers, N. F., Moraal, B., Barkhof, F., Teunissen, C. E., Killestein, J., & van Kempen, Z. L. E. (2021). Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients. Multiple sclerosis journal - experimental, translational and clinical, 7(2). https://doi.org/10.1177/20552173211013831

@article{07d15bb8768047ed85be1eb0335a1ace,

title = "Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients",

abstract = "Ocrelizumab is often used as an alternative therapy in natalizumab-treated MS patients at risk for progressive multifocal leukoencephalopathy (PML). Our objective was to assess efficacy and safety of JC-virus positive patients switching (either directly or indirectly) from natalizumab to ocrelizumab. Forty-two patients were included from an observational cohort (median follow-up 21 months). No evidence of disease activity was found in 83% of direct switchers and 50% of indirect switchers. Two direct switchers were diagnosed with carry-over PML. Our data support a direct switch for adequate disease suppression, although carry-over PML illustrates the dilemma when choosing between a direct or indirect switch.",

keywords = "JC virus, Multiple sclerosis, disease activity, natalizumab, ocrelizumab, progressive multifocal leukoencephalopathy",

author = "{van Lierop}, {Z. Y. G. J.} and Toorop, {A. A.} and Coerver, {E. M. E.} and Willemse, {E. A. J.} and Strijbis, {E. M. M.} and Kalkers, {N. F.} and B. Moraal and F. Barkhof and Teunissen, {C. E.} and J. Killestein and {van Kempen}, {Z. L. E.}",

note = "Funding Information: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Dutch MS Research Foundation [grant number 18-358f]. Publisher Copyright: {\textcopyright} The Author(s) 2021. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

doi = "https://doi.org/10.1177/20552173211013831",

language = "English",

volume = "7",

journal = "Multiple sclerosis journal - experimental, translational and clinical",

issn = "2055-2173",

publisher = "SAGE Publications Inc.",

number = "2",

}

van Lierop, ZYGJ , Toorop, AA , Coerver, EME , Willemse, EAJ , Strijbis, EMM , Kalkers, NF , Moraal, B , Barkhof, F , Teunissen, CE , Killestein, J & van Kempen, ZLE 2021, 'Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients', Multiple sclerosis journal - experimental, translational and clinical, vol. 7, no. 2. https://doi.org/10.1177/20552173211013831

TY - JOUR

T1 - Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients

AU - van Lierop, Z. Y. G. J.

AU - Toorop, A. A.

AU - Coerver, E. M. E.

AU - Willemse, E. A. J.

AU - Strijbis, E. M. M.

AU - Kalkers, N. F.

AU - Moraal, B.

AU - Barkhof, F.

AU - Teunissen, C. E.

AU - Killestein, J.

AU - van Kempen, Z. L. E.

N1 - Funding Information: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Dutch MS Research Foundation [grant number 18-358f]. Publisher Copyright: © The Author(s) 2021. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021

Y1 - 2021

N2 - Ocrelizumab is often used as an alternative therapy in natalizumab-treated MS patients at risk for progressive multifocal leukoencephalopathy (PML). Our objective was to assess efficacy and safety of JC-virus positive patients switching (either directly or indirectly) from natalizumab to ocrelizumab. Forty-two patients were included from an observational cohort (median follow-up 21 months). No evidence of disease activity was found in 83% of direct switchers and 50% of indirect switchers. Two direct switchers were diagnosed with carry-over PML. Our data support a direct switch for adequate disease suppression, although carry-over PML illustrates the dilemma when choosing between a direct or indirect switch.

AB - Ocrelizumab is often used as an alternative therapy in natalizumab-treated MS patients at risk for progressive multifocal leukoencephalopathy (PML). Our objective was to assess efficacy and safety of JC-virus positive patients switching (either directly or indirectly) from natalizumab to ocrelizumab. Forty-two patients were included from an observational cohort (median follow-up 21 months). No evidence of disease activity was found in 83% of direct switchers and 50% of indirect switchers. Two direct switchers were diagnosed with carry-over PML. Our data support a direct switch for adequate disease suppression, although carry-over PML illustrates the dilemma when choosing between a direct or indirect switch.

KW - JC virus

KW - Multiple sclerosis

KW - disease activity

KW - natalizumab

KW - ocrelizumab

KW - progressive multifocal leukoencephalopathy

UR - http://www.scopus.com/inward/record.url?scp=85107232592&partnerID=8YFLogxK

U2 - https://doi.org/10.1177/20552173211013831

DO - https://doi.org/10.1177/20552173211013831

M3 - Article

C2 - 34123391

SN - 2055-2173

VL - 7

JO - Multiple sclerosis journal - experimental, translational and clinical

JF - Multiple sclerosis journal - experimental, translational and clinical

IS - 2

ER -

Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients

Abstract

Keywords

Access to Document

Other files and links

Cite this